An extracorporeal blood treatment device includes an extracorporeal circuit, a dialyzer, a dialyzing liquid circuit and a control unit. A venous section and an arterial section of the extracorporeal circuit each includes a sensor configured to acquire a hematocrit percentage in a liquid flowing through the corresponding section. The control unit controls reinfusion of blood such that a dialyzing liquid is supplied from the dialyzing liquid circuit via a dialyzer membrane to the extracorporeal circuit, which displaces blood present in the extracorporeal circuit towards a patient to return the blood to the patient via the venous section and arterial section. Reinfusion in the corresponding section of the extracorporeal circuit is discontinued if it is acquired by the corresponding sensor or calculated or predicted by the control unit based on information acquired by the corresponding sensor that the hematocrit percentage falls below a predetermined limit value.

A drug administration controller has a sensor that generates a sensor signal to a physiological measurement device, which measures a physiological parameter in response. A control output responsive to the physiological parameter or a metric derived from the physiological parameter causes a drug administration device to affect a treatment of a person, such as by initiating, pausing, halting or adjusting a dosage of drugs administered to the person.

A ureteral catheter is provided, including a drainage lumen including a proximal portion and a distal portion configured to be positioned in a patient's kidney, renal pelvis, and/or in the ureter adjacent to the renal pelvis, the distal portion including a retention portion for maintaining positioning of the distal portion of the drainage lumen, the retention portion including at least two openings on a sidewall of the retention portion for permitting fluid flow into the drainage lumen wherein a total area of a proximal most opening of the at least two openings is less than a total area of more distal opening(s) nearer to the distal end of the drainage lumen, and wherein when negative pressure is applied through the ureteral catheter, fluid is drawn into the ureteral catheter through the at least two openings.

Techniques and apparatuses for determining an estimated cardiac output for a patient during dialysis treatment are described. In one embodiment, for example, an apparatus may include a memory and logic coupled to the memory. The logic may be configured to determine an upper body oxygen consumption for a patient, determine, during a dialysis process: a hemoglobin concentration and a venous oxygen saturation measured via an optical blood monitor operably coupled to an extracorporeal circuit of a dialysis system performing the dialysis process; an arterial oxygen saturation measured via a pulse oximeter operably coupled to the extracorporeal circuit; an arterial-venous oxygen content difference based on the arterial oxygen saturation and the venous oxygen saturation; and an upper body blood flow (UBBF) as (upper body oxygen consumption)/(arterial-venous oxygen content difference), and determine a treatment recommendation based on the upper body blood flow. Other embodiments are described.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which a volume of plasma product (i.e., anticoagulated plasma) so that that the targeted volume of pure plasma in the plasma product is determined based on donor-specific characteristics. In particular, the targeted amount of pure plasma to be collected is based on the weight, or the weight and the height, of the donor. The targeted volume of pure plasma to be collected, TVP, may be a multiple of the donor's weight. Alternatively, TVP may be a multiple of the donor's total blood volume, TBV, with the TBV of the donor being determined based on the donor's weight and height. A target volume for the plasma product to be collected, TVPP, is established, and separation of whole blood into a plasma component and a second component continues until the volume of plasma product in a collection container equals TVPP.

System and methods are provided for treating a patient that include a delivery device sized for introduction into a target site within a patient's body, a source of one or more therapeutic and/or diagnostic agents coupled to the delivery device, and a tubular member sized for introduction into the patient's vasculature to isolate the thoracic duct. Once the thoracic duct is isolated, fluid may be removed from the thoracic duct, e.g., to prevent the agents that transit from the target site into the thoracic duct from entering the patient's vasculature, and/or to modulate flow through the thoracic duct to modulate concentration and/or resident time of the agents at the target site. The one or more agents may include particles sized for preferential transit into the lymphatic system.

A method for removing excess fluid from a patient with hemodilution is provided. The method includes: deploying a urinary tract catheter into the patient such that flow of urine from the ureter and/or kidney is transported within a drainage lumen of the catheter; applying negative pressure to the ureter and/or kidney through the drainage lumen of the catheter to extract urine from the patient; periodically measuring a hematocrit value of the patient; and if the measured hematocrit value is greater than a predetermined threshold value, ceasing the application of the negative pressure to the ureter and/or kidney. A system for removing excess fluid from a patient with hemodilution including a ureteral catheter and a pump is also provided.

Embodiments of the disclosure provide a method for determining beginning blood volume of a patient during dialysis (e.g., hemodialysis). Ultrafiltration rates are determined at different time stamps during dialysis by obtaining a blood flowrate measurement and hematocrit measurements at input port and output port of a dialyzer connected to the patient. The flowrate and hematocrit measurements are used to determine fluid removed from the patient during dialysis. The ultrafiltration rates and fluid removed from the patient are used to determine the beginning blood volume of the patient.

Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “η” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

A system for collecting plasma comprises a separator to separate whole blood from a donor into a plasma product and red blood cells, an anticoagulant line to introduce anticoagulant to the whole blood, a touchscreen, and a controller. The controller is configured to receive donor parameters electronically from a donor management system. The controller is configured to use a target volume for plasma product and/or raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for plasma product and/or raw plasma based on the total donor blood volume. The controller is configured to control the system to operate at least three draw and return phases to withdraw whole blood from a donor and separate the whole blood into the plasma product and the red blood cells and to return the red blood cells to the donor.